Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $188.3 million.

  • Editas Medicine's Total Liabilities rose 2393.49% to $188.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $188.3 million, marking a year-over-year increase of 2393.49%. This contributed to the annual value of $207.3 million for FY2024, which is 3815.84% up from last year.
  • Latest data reveals that Editas Medicine reported Total Liabilities of $188.3 million as of Q3 2025, which was up 2393.49% from $191.4 million recorded in Q2 2025.
  • Editas Medicine's 5-year Total Liabilities high stood at $207.3 million for Q4 2024, and its period low was $110.3 million during Q1 2022.
  • In the last 5 years, Editas Medicine's Total Liabilities had a median value of $145.9 million in 2024 and averaged $150.3 million.
  • In the last 5 years, Editas Medicine's Total Liabilities plummeted by 3870.96% in 2021 and then soared by 3815.84% in 2024.
  • Quarter analysis of 5 years shows Editas Medicine's Total Liabilities stood at $123.8 million in 2021, then increased by 24.06% to $153.6 million in 2022, then decreased by 2.33% to $150.1 million in 2023, then skyrocketed by 38.16% to $207.3 million in 2024, then decreased by 9.17% to $188.3 million in 2025.
  • Its Total Liabilities was $188.3 million in Q3 2025, compared to $191.4 million in Q2 2025 and $201.2 million in Q1 2025.